Humoral response to the pfizer bnt162b2 vaccine in patients undergoing maintenance hemodialysis

Ayelet Grupper, Nechama Sharon, Talya Finn, Regev Cohen, Meital Israel, Amir Agbaria, Yoav Rechavi, Idit F. Schwartz, Doron Schwartz, Yonatan Lellouch, Moshe Shashar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background and objectives Coronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality in patients on maintenance hemodialysis. Patients on dialysis tend to have a reduced immune response to infection or vaccination. We aimed to assess, for the first time to the best of our knowledge, the humoral response following vaccination with the BNT162b2 vaccine in patients on maintenance hemodialysis and the factors associated with it. Design, setting, participants, & measurements The study included 56 patientson maintenance hemodialysis (dialysis group) and a control group composed of 95 health care workers. All participants had received two doses of the BNT162b2 (Pfizer-BioNTech) vaccine. The serology testing was done using Quant II IgG anti-Spike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay by Abbott a median of 30 days after receipt of the second dose of the vaccine. Results All subjects in the control group developed an antibody response compared with 96% (54 of 56) positive responders in the dialysis group. The IgG levels in the dialysis group (median, 2900; interquartile range, 1128–5651) weresignificantly lower than in the control group (median, 7401; interquartile range, 3687–15,471). A Mann–Whitney U test indicated that this difference was statistically significant (U=1238; P<0.001). There was a significant inverse correlation of age and IgG levels in both groups. The odds of being in the lower quartile were significantly higher for older individuals (odds ratio, 1.11 per year of age; 95% confidence interval, 1.08 to 1.20; P=0.004) and for the dialysis group compared with the control group (odds ratio, 2.7; 95% confidence interval, 1.13 to 7.51; P=0.05). Within the dialysis group, older age and lower lymphocyte count were associated with antibody response in the lower quartile (odds ratio, 1.22 per 1-year older; 95% confidence interval, 1.13 to 1.68; P=0.03 and odds ratio, 0.83 per 10-e3/μl-higher lymphocyte count; 95% confidence interval, 0.58 to 0.97; P=0.05). Conclusions Although most patients on maintenance hemodialysis developed a substantial humoral response following the BNT162b2 vaccine, it was significantly lower than controls. Age was an important factor in the humoral response, regardless of chronic medical conditions.

Original languageEnglish
Pages (from-to)1037-1042
Number of pages6
JournalClinical journal of the American Society of Nephrology : CJASN
Issue number7
StatePublished - Jul 2021


Dive into the research topics of 'Humoral response to the pfizer bnt162b2 vaccine in patients undergoing maintenance hemodialysis'. Together they form a unique fingerprint.

Cite this